Key result
Mepivacaine spinal anesthesia achieves ~70% early ambulation, beating both hyperbaric and isobaric bupivacaine.
Why the study?
Spinal anesthesia can delay early ambulation after total hip arthroplasty, particularly with bupivacaine, whereas intermediate-acting mepivacaine could potentially enable earlier ambulation.
Does mepivacaine improve early ambulation compared to bupivacaine in patients undergoing primary total hip arthroplasty?
RCT (n=154)
1:1:1
Does mepivacaine improve early ambulation compared to bupivacaine in patients undergoing primary total hip arthroplasty?
Absolute Event Rate: 70% vs 37.7%
p-value: p=< 0.001
Mepivacaine spinal anesthesia facilitates earlier ambulation and increases same-day discharge rates compared to bupivacaine in total hip arthroplasty.
Supports mepivacaine for earlier ambulation after hip arthroplasty; confirms hypothesis and extends spinal anesthesia options in recovery protocols.
BACKGROUND: Early ambulation after total hip arthroplasty predicts early discharge. Spinal anesthesia is preferred by many practices but can delay ambulation, especially with bupivacaine. Mepivacaine, an intermediate-acting local anesthetic, could enable earlier ambulation than bupivacaine. This study was designed to test the hypothesis that patients who received mepivacaine would ambulate earlier than those who received hyperbaric or isobaric bupivacaine for primary total hip arthroplasty. METHODS: This randomized controlled trial included American Society of Anesthesiologists Physical Status I to III patients undergoing primary total hip arthroplasty. The patients were randomized 1:1:1 to 52.5 mg of mepivacaine, 11.25 mg of hyperbaric bupivacaine, or 12.5 mg of isobaric bupivacaine for spinal anesthesia. The primary outcome was ambulation between 3 and 3.5 h. Secondary outcomes included return of motor and sensory function, postoperative pain, opioid consumption, transient neurologic symptoms, urinary retention, intraoperative hypotension, intraoperative muscle tension, same-day discharge, length of stay, and 30-day readmissions. RESULTS: Of 154 patients, 50 received mepivacaine, 53 received hyperbaric bupivacaine, and 51 received isobaric bupivacaine. Patient characteristics were similar among groups. For ambulation at 3 to 3.5 h, 35 of 50 (70.0%) of patients met this endpoint in the mepivacaine group, followed by 20 of 53 (37.7%) in the hyperbaric bupivacaine group, and 9 of 51 (17.6%) in the isobaric bupivacaine group (P < 0.001). Return of motor function occurred earlier with mepivacaine. Pain and opioid consumption were higher for mepivacaine patients in the early postoperative period only. For ambulatory status, 23 of 50 (46.0%) of mepivacaine, 13 of 53 (24.5%) of hyperbaric bupivacaine, and 11 of 51 (21.5%) of isobaric bupivacaine patients had same-day discharge (P = 0.014). Length of stay was shortest in mepivacaine patients. There were no differences in transient neurologic symptoms, urinary retention, hypotension, muscle tension, or dizziness. CONCLUSIONS: Mepivacaine patients ambulated earlier and were more likely to be discharged the same day than both hyperbaric bupivacaine and isobaric bupivacaine patients. Mepivacaine could be beneficial for outpatient total hip arthroplasty candidates if spinal is the preferred anesthesia type.
No takes yet. Share an insight, caveat, or question.
Schwenk et al. (2020) conducted an RCT in primary total hip arthroplasty (n=154). Mepivacaine vs. hyperbaric bupivacaine (11.25 mg) or isobaric bupivacaine (12.5 mg) was evaluated on ambulation between 3 and 3.5 h (p=< 0.001). Mepivacaine spinal anesthesia resulted in a higher rate of ambulation between 3 and 3.5 hours (70.0%) compared to hyperbaric (37.7%) and isobaric bupivacaine (17.6%) (P < 0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: